$66.9
Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $66.39 – an increase of 1.45% over the previous week. Incyte Corporation employs 2,524 staff and has a trailing 12-month revenue of around $3.9 billion.
What's in this guide?
- INCY shares summary
- Compare share dealing platforms
- Is INCY stock a buy or sell?
- Stock performance over time
- Can I short INCY shares?
- Are INCY shares over-valued?
- Incyte Corporation's financials
- How volatile are INCY shares?
- Does Incyte Corporation pay a dividend?
- Have INCY shares ever split?
- Other common questions
Our top picks for where to buy Incyte Corporation stock
- Earn 4.5% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Unlimited bonus amounts Oct 16-27
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Incyte Corporation stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – INCY. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Incyte Corporation stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Incyte Corporation stock price (NASDAQ: INCY)
Use our graph to track the performance of INCY stocks over time.Incyte Corporation shares at a glance
Latest market close | $66.39 |
---|---|
52-week range | $50.27 - $70.36 |
50-day moving average | $64.38 |
200-day moving average | $60.52 |
Wall St. target price | $73.95 |
PE ratio | 161.6829 |
Dividend yield | N/A |
Earnings per share (TTM) | $0.41 |
Is it a good time to buy Incyte Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Incyte Corporation price performance over time
Historical closes compared with the close of $66.39 from 2024-10-18
1 week (2024-10-14) | 1.45% |
---|---|
1 month (2024-09-20) | 0.99% |
3 months (2024-07-19) | 0.79% |
6 months (2024-04-19) | 26.82% |
1 year (2023-10-20) | 20.42% |
---|---|
2 years (2022-10-21) | -5.94% |
3 years (2021-10-21) | 0.79% |
5 years (2019-10-21) | 78.59 |
Is Incyte Corporation stock undervalued or overvalued?
Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Incyte Corporation's P/E ratio
Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 162x. In other words, Incyte Corporation shares trade at around 162x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Incyte Corporation's PEG ratio
Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5583. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Incyte Corporation's EBITDA
Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $124.2 million.
The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.
Incyte Corporation financials
Revenue TTM | $3.9 billion |
---|---|
Gross profit TTM | $1.6 billion |
Return on assets TTM | 0.39% |
Return on equity TTM | 2.52% |
Profit margin | 2.52% |
Book value | $15.65 |
Market Capitalization | $12.8 billion |
TTM: trailing 12 months
Incyte Corporation share dividends
We're not expecting Incyte Corporation to pay a dividend over the next 12 months.
Have Incyte Corporation's shares ever split?
Incyte Corporation's shares were split on a 2:1 basis on 31 August 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.
Incyte Corporation share price volatility
Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as $50.27 up to $70.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 0.735. This would suggest that Incyte Corporation's shares are less volatile than average (for this exchange).
Incyte Corporation overview
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.
Frequently asked questions
nullWhat percentage of Incyte Corporation is owned by insiders or institutions?
Currently 2.051% of Incyte Corporation shares are held by insiders and 105.934% by institutions. How many people work for Incyte Corporation?
Latest data suggests 2,524 work at Incyte Corporation. When does the fiscal year end for Incyte Corporation?
Incyte Corporation's fiscal year ends in December. Where is Incyte Corporation based?
Incyte Corporation's address is: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 What is Incyte Corporation's ISIN number?
Incyte Corporation's international securities identification number is: US45337C1027 What is Incyte Corporation's CUSIP number?
Incyte Corporation's Committee on Uniform Securities Identification Procedures number is: 45337C102
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question